Nkarta, Inc.
NASDAQ: NKTXSouth San Francisco, US · 4 known investors
Nkarta develops engineered natural killer (NK) cell therapies aimed at treating autoimmune and rheumatic diseases such as lupus. Its proprietary cell technology is designed to reset a disordered immune system by targeting dysfunctional or abnormal cells.
BiotechHealthtech
Investors · 4
Competitors · 3
by search overlapNektar Therapeutics23 shared keywordsNektar develops novel medicines targeting autoimmune and inflammatory conditions through immune science, aiming to restore immune balance. It operates in the biotechnology and immunology therapeutics space.
Seeking Alpha18 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Robinhood18 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Nkarta, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Nkarta, Inc. do?
- Nkarta develops engineered natural killer (NK) cell therapies aimed at treating autoimmune and rheumatic diseases such as lupus. Its proprietary cell technology is designed to reset a disordered immune system by targeting dysfunctional or abnormal cells.
- Who are Nkarta, Inc.'s investors?
- Nkarta, Inc.'s investors include Samsara BioCapital, SR One Capital Management, New Enterprise Associates (NEA), Norwest Venture Partners.
- Where is Nkarta, Inc. headquartered?
- Nkarta, Inc. is headquartered in South San Francisco, US.